Innate Pharma: AZN should come back… and it may be better than expected

BUY, Fair Value EUR19 (+40%)
News published on October Wednesday 7, 2015
Share on

We reiterate our positive stance regarding the potential of IPH2201 as an add-on for the durvalumab franchise following a meeting with Pierre Dordion (IPH’s Chief Medical Officer). Our base-case scenario on the future development of IPH2201/durvalumab is not only confirmed… but may exceed our current expectations (either in solid tumors or in haematological malignancies).


For more information, please contact marketing@bryangarnier.com 

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities